Journal ArticleDOI
Improved Graft Survival after Renal Transplantation in the United States, 1988 to 1996
Sundaram Hariharan,Christopher P. Johnson,Barbara A. Bresnahan,S. Taranto,Matthew McIntosh,Donald Stablein +5 more
TLDR
There has been a substantial increase in short-term and long-term survival of kidney grafts from both living and cadaveric donors since 1988.Abstract:
Background The introduction of cyclosporine has resulted in improvement in the short-term outcome of renal transplantation, but its effect on the long-term survival of kidney transplants is not known. Methods We analyzed the influence of demographic characteristics (age, sex, and race), transplant-related variables (living or cadaveric donor, panel-reactive antibody titer, extent of HLA matching, and cold-ischemia time), and post-transplantation variables (presence or absence of acute rejection, delayed graft function, and therapy with mycophenolate mofetil and tacrolimus) on graft survival for all 93,934 renal transplantations performed in the United States between 1988 and 1996. A regression analysis adjusted for these variables was used to estimate the risk of graft failure within the first year and more than one year after transplantation. Results From 1988 to 1996, the one-year survival rate for grafts from living donors increased from 88.8 to 93.9 percent, and the rate for cadaveric grafts increased...read more
Citations
More filters
Journal ArticleDOI
Neoral monitoring 2 hours post-dose and the pediatric transplant patient
TL;DR: This review presents the information available supporting cyclosporin drug concentration drawn two hours post dose (C‐2) in children who have been transplanted as the best single indicator of CsA exposure.
Journal ArticleDOI
Consequences of Eliminating HLA‐B in Deceased Donor Kidney Allocation to Increase Minority Transplantation
TL;DR: Overall, policies to increase minority transplants by increasing donation rates may prove more cost effective than the elimination of HLA‐B matching from deceased donor kidney allocation, and save $5400 for each QALY that is lost.
Journal ArticleDOI
Chronic transplant dysfunction and transplant arteriosclerosis: new insights into underlying mechanisms.
Jan-Luuk Hillebrands,Jan Rozing +1 more
TL;DR: It is argued here that host-derived cells contribute to the development of these vascular lesions, and it is proposed that TA results from a normal vascular repair process that proceeds beyond the needs of functional repair.
Journal ArticleDOI
Plasma procalcitonin is an independent predictor of graft failure late after renal transplantation.
Rutger M. van Ree,Aiko P. J. de Vries,Leendert H. Oterdoom,Marc A. Seelen,Ron T. Gansevoort,Jan P. Schouten,Joachim Struck,Gerjan Navis,Reinold O. B. Gans,Jaap J. Homan van der Heide,Willem J. van Son,Stephan J. L. Bakker +11 more
TL;DR: The data suggest that PCT in RTR reflects ongoing inflammation in parenchyma of transplanted kidneys, and could be of use as an early biomarker for chronic transplant dysfunction.
Journal ArticleDOI
T helper subsets & regulatory T cells: rethinking the paradigm in the clinical context of solid organ transplantation.
TL;DR: Current understanding of the Th subsets paradigm is highlighted, and how these unique subpopulations impact host responses towards solid organ allografts could potentially offer opportunities for immunological interventions in solid organ transplantation.
References
More filters
Book ChapterDOI
Nonparametric Estimation from Incomplete Observations
Edward L. Kaplan,Paul Meier +1 more
TL;DR: In this article, the product-limit (PL) estimator was proposed to estimate the proportion of items in the population whose lifetimes would exceed t (in the absence of such losses), without making any assumption about the form of the function P(t).
Journal ArticleDOI
Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group.
TL;DR: This study demonstrated that MMF administered at a dosage of 2 g or 3 g daily, in combination with maintenance CsA and corticosteroids as triple therapy following ATGAM® induction therapy, is more effective than an otherwise identical regimen that includes azathioprine instead of MMF in preventing acute allograft rejection in first cadaveric renal transplant patients.
Journal ArticleDOI
A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group
TL;DR: Tacrolimus is more effective than cyclosporine in preventing acute rejection in cadaveric renal allograft recipients, and significantly reduces the use of antilymphocyte antibody preparations.
Journal ArticleDOI
Risk factors for chronic rejection in renal allograft recipients.
P. S. Almond,A. J. Matas,K. J. Gillingham,David L. Dunn,William D. Payne,Paul F. Gores,Rainer W.G. Gruessner,J. S. Najarian +7 more
TL;DR: In this article, the authors found that acute rejection, CsA dosage < 5 mg/kg/day at 1 year, and infection are the major risk factors for the development of chronic rejection.
Related Papers (5)
The Banff 97 working classification of renal allograft pathology
Lorraine C. Racusen,Kim Solez,Robert B. Colvin,Stephen M. Bonsib,Maria Castro,Tito Cavallo,Byron P. Croker,A. Jake Demetris,Cynthia B. Drachenberg,Agnes B. Fogo,Peter N. Furness,Lillian W. Gaber,Ian W. Gibson,Dennis Glotz,J. Goldberg,Joseph P. Grande,Philip F. Halloran,H.E. Hansen,Barry Hartley,Pekka Hayry,Claire M. Hill,Ernesto O. Hoffman,Lawrence G. Hunsicker,Anne S. Lindblad,Niels Marcussen,M. J. Mihatsch,Tibor Nadasdy,Peter Nickerson,T. Steen Olsen,John C. Papadimitriou,Parmjeet Randhawa,David C. Rayner,Ian S.D. Roberts,Stephen Rose,D. Rush,Luis Salinas-Madrigal,Daniel R. Salomon,Stale Sund,Eero Taskinen,Kiril Trpkov,Yutaka Yamaguchi +40 more